Misop Han, M.D.

David Hall McConnell Professor of Urology and Oncology
Medical Director, Credentials Committee, Johns Hopkins Hospital
Director, Urology Informatics

Marburg 146,
600 N. Wolfe St.,
Baltimore, Maryland 21287-2101

Appointments: 410-955-6100

Office: 410-502-7454

Email: mhan1@jhmi.edu

Fax: 410-955-0833

Dr. Misop Han is professor of urology and oncology at the Johns Hopkins Hospital. Dr. Han is a board-certified urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. When meeting with a patient, Dr. Han carefully reviews the patient's individual situation to determine with the patient the best approach to treatment. 

Dr. Han specializes in:

  1. Prostate Cancer
  2. Robotic Prostatectomy
  3. Robotic Nephrectomy
  4. Nerve-sparing Prostatectomy
  5. Laparoscopic Nephrectomy
  6. Benign Prostatic Hyperplasia (BPH)
  7. Kidney Cancer
Dr. Han received his undergraduate and medical degrees at Johns Hopkins School of Medicine. After an internship in surgery and residencies in surgery and urology, also at Johns Hopkins, he worked as an Assistant Professor of Urology at the Feinberg School of Medicine at Northwestern University and as a urologist at Northwestern Memorial Hospital in Chicago, Illinois. While there, he headed Northwestern University's clinical database for prostate cancer research. In 2006, he joined the Johns Hopkins faculty.

At Johns Hopkins Hospital, Dr. Han is actively involved in researching what happens to men following surgery for prostate cancer.  He has published extensively in these subjects. Click here for his publications.  Click here for the outcome of radical prostatectomy and prediction modeling (Han Tables). Dr. Han's research and clinical trials also involve urologic robotics for image-guided surgery.

Dr. Han has received international and national recognition for his research involving the outcomes of surgeries for patients with prostate cancer. He is a member of the American Urological Association and the American Medical Association, and is certified by the American Board of Urologists.


School of Medicine
Johns Hopkins University, Baltimore, MD
Biomedical Engineering
Whiting School of Engineering
Johns Hopkins University, Baltimore, MD


Resident in Urological Surgery
2002-June 2006
  • The James Buchanan Brady Urological Institute
    Johns Hopkins Hospital, Baltimore, Maryland.
    Chairman: Drs. Patrick C. Walsh and Alan W. Partin
Resident in General Surgery
  • Department of General Surgery
    Johns Hopkins Hospital, Baltimore, Maryland
    Chairman: Dr. John L. Cameron
Intern in General Surgery
  • Department of General Surgery
    Johns Hopkins Hospital, Baltimore, Maryland
    Chairman: Dr. John L. Cameron


Free Access to abstracts at PubMed

  1. Peer-reviewed Original Science Research

    1. North RB, Han M, Zahurak M, Kidd DH: Radiofrequency lumbar facet denervation: analysis of prognostic factors. Pain. 1994; 57(1): 77-83.
    2. Han M, Burnett AL, Fishman EK, Marshall FF: The natural history and treatment of adrenal myelolipoma. J Urol. 1997;157(4):1213-6.
    3. Han M, Schoenberg MP: The use of molecular diagnostics in bladder cancer.  Urologic Onc. 2000;5(3):87-92.
    4. Han M, Nelson JB: Non-steroidal anti-androgens on prostate cancer-current treatment practice. Exp Opin Pharmacotherapy. 2000; 1(3): 443-449.
    5. Han M, Partin AW, Walsh PC, Rodriguez R: Ability of the 1992 and 1997 American Joint Committee on Cancer (AJCC) staging systems for prostate cancer to predict progression free survival following radical prostatectomy for T2 disease.  J Urol. 2000; 164 (1): 89-92.
    6. Han M, Snow PB, Epstein JI, Chan TY, Jones KA, Walsh PC and Partin AW: A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors following radical prostatectomy, Urology. 2000; 56(6):994-9.
    7. Han M, Potter SR, Partin AW: The role of free Prostate-Specific Antigen in prostate cancer detection, Current Urology Reports. 2000; 1:78-82.
    8. Han M, Snow PB, Brandt JM, Partin AW: Evaluation of artificial neural networks for the prediction of pathological stage in prostate cancer, Cancer. 2001;  91(S8): 1661-6.
    9. Han M, Pound CR, Potter SR, Partin AW, Epstein JI, Walsh PC: Isolated local recurrence is rare following radical prostatectomy for men with Gleason 7 diseases and positive surgical margins: Therapeutic implications, J Urol. 2001; 165(3): 864-6.
    10. Batuello JT, Gamito EJ, Crawford ED, Han M, Partin AW, McLeod DG and O’Connell C: An artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer, Urology. 2001;  57(3): 481-5.
    11. Han M, Piantadosi S, Zahurak ML, Sokoll LJ, Chan DW, Epstein JI, Walsh PC and Partin AW: Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology. 2001; 57(4): 707-11.
    12. Han M, Partin AW, Epstein JI, Walsh PC: Era-specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer, J Urol. 2001;166(2): 416-9.
    13. Han M, Partin AW: The role of ProstaScint scan (111In-capromab pendetide scan), Reviews in Urology. 2001; 3 (4): 165-71.
    14. Barocas DA, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, and Partin AW: Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer, Urology. 2001; 58(5): 746-51.
    15. Roberts WW, Bergstralh EJ, Blute ML, Slezak JM, Carducci M, Han M, Epstein JI, Eisenberger MA, Walsh PC and Partin AW: Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology. 2001; Jun;57(6): 1033-7.
    16. Han M, Partin AW: Nomograms for Clinically Localized Prostate Cancer. Part I.  Radical Prostatectomy, Seminars in Urologic Oncology. 2000; 20 (2): 123-30.
    17. Gretzer MB, Trock BJ, Han M, Walsh PC: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria, J Urol. 2002; 168(4 pt 1): 1419-22.
    18. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC: Prediction of biochemical (PSA) recurrence following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517-23
    19. Khan MA, Han M, Partin AW, Epstein JI, Walsh PC: Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update. Urology. 2003;62(1): 86-91.
    20. Han M, Partin AW, Chan DY, Walsh PC: An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series.  J Urol. 2004;171 (1): 23-6.
    21. Han M, Nadler RB, Catalona WJ: Point and Counterpoint Debate on the Approaches to Radical Prostatectomy, In Favor of the Traditional Radical Retropubic Prostatectomy (RRP).  Contemporary Urology. 2004;16(2): 38-45.
    22. Han M, Gann PH, Catalona WJ. Prostate-specific antigen and screening for prostate cancer.  Med Clin North Am. 2004;88(2): 245-65.
    23. Antenor AV, Han M, Roehl KA, Nadler RB, Catalona WJ: Relation between initial screening PSA level and subsequent prostate cancer detection in a longitudinal screening population. J Urol. 2004; 172(2): 90-93.
    24. Roehl KA, Han M, Ramos CG, Antenor JV, Catalona WJ: Cancer Progression and Survival Rates After Anatomic Radical Retropubic Prostatectomy in 3,478 Consecutive Patients: Long-Term Results. J Urol. 2004;172 (4): 910-4.
    25. Kundu SD, Roehl KA, Eggener SE, Antenor JV, Han M, Catalona WJ: Potency, Continence and Complications in 3,477 Consecutive Radical Retropubic Prostatectomies. J Urol. 2004;172 (6):2227-31.
    26. Han M, Brannigan RE, Antenor JV, Roehl KA, Catalona WJ: The Association between Hematospermia and Prostate Cancer. J Urol. 2004;172 (6):2189-92.
    27. Gonzalez C, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ: Preoperative PSA Level Significantly Associated with Interval to Biochemical Progression After Radical Retropubic Prostatectomy. Urology. 2004; 64 (4):723-8.
    28. Kundu SD, Han M, Catalona WJ: Should an Isolated Humeral Lesion Detected During Prostate Cancer Metastatic Survey be Biopsied? J Urol. 2004;172(5 Pt 1): 1825-6.
    29. Eggener SE, Roehl KA, Smith ND, Antenor JV, Han M, Catalona WJ: Contemporary Survival Results and the Role of Radiation Therapy in Patients with Seminal Vesicle Invasion Following Radical Prostatectomy. J Urol. 2005;173 (4): 1150-5.
    30. Antenor JV, Roehl KA, Eggener SE, Kundu SD, Han M, Catalona WJ: Preoperative PSA and Progression-Free Survival Following Radical Prostatectomy for Stage T1c disease. Urology. 2005; 66(1): 156-60.
    31. Loeb S, Han M, Roehl DA, Antenor JV, Catalona WJ: Accuracy of Prostate Size Estimation by Digital Rectal Examination Versus Transrectal Ultrasonography. J Urol. 2005; 173(1):63-5.
    32. Kundu SD, Grubb RL, Roehl KA, Antenor JV, Han M, Catalona WJ: Delays in Cancer Detection Using Two- and Four-Year Screening Intervals for Prostate Cancer Screening with Initial PSA Less than 2 ng/mL. J Urol. 2005;173 (4): 1116-20.
    33. Pazona J, Han M, Hawkins SA, Catalona WJ: Salvage Radiation Therapy for PSA Progression Following Radical Prostatectomy: 10-year Outcome Estimates. J Urol. 2005; 174(4 Pt 1):1282-6.
    34. Dale W, Bilir P, Han M, Meltzer D: The role of Anxiety in Prostate Carcinoma. Cancer. 2005;104(3):467-78.
    35. Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ: Pathological Characteristics of Prostate Cancer Detected Through Prostate Specific Antigen Based Screening.  J Urology. 2006;175(3):902-6.
    36. Catalona WJ, Loeb S, Han M: Viewpoint: Expanding Prostate Cancer Screening.  Ann Intern Med. 2006;  144(6): 441-3.
    37. Yang XJ, Sugimura J, Schafernak KT, Tretiakova MS, Han M, Vogelzang NJ, Furge K, The BT. Classification of renal neoplasms based on molecular signatures.  J Urology. 2006;175(6): 2302-2306.
    38. Loeb S, Roehl KA, Yu X, Antenor JA, Han M, Gashti SN, Yang XJ, Catalona WJ: Lymphovasucalr Invasion in Radical Prostatectomy Specimens: Predication of Adverse Pathological Features and Biochemical Progression.  Urology. 2006; 68(1): 99-103.
    39. Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, Catalona WJ: Comparison of Methods of Calculating Prostate Specific Antigen Velocity.  J Urology. 2006; 176(6): 2427-2431.
    40. Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, Freedland SJ. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center.  J Urology. 2006; 176(2): 515-519.
    41. Jang TL, Han M, Catalona WJ: More Favorable Tumor Features and Progression-Free Survival Rates in a Longitudinal Prostate Cancer Screening Study: PSA Era- and Threshold-Specific Effects. Urology   2006; 67(2): 343-8.
    42. Yu X, Loeb S, Roehl KA, Han M, Catalona WJ: The Association Between Total Prostate Specific Antigen Concentration and Prostate Specific Antigen Velocity.  J Urology. 2006; 177(4): 1298-302.
    43. Loeb S, Roehl KA, Yu X, Han M, Catalona WJ. Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.  Urology. 2007; 69(1): 108-12.
    44. Wang KL, Weinrach DM, Luan C, Han M, Lin F, The BY, Yang X: Renal Papillary Adenoma-A Putative Precursor of Papillary Renal Cell Carcinoma.  Human Pathology. 2007; 38(2): 239-46.
    45. Loeb S, Yu X, Nadller RB, Roehl KA, Han M, Hawkins SAR, Catalona WJ. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?  J Urology. 2007; 177(1): 102-6.
    46. Chuang ST, Adley B, Han M, Lin F, Yang XJ, Catalona WJ. Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostate cancer. Histopathology. 2008; 52(2): 247-50.
    47. Yg’ CR, Yu X, Loeb S, Desireddi VN, Han M, Graif T, Catalona WJ. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol. 2007; 178: 860-3.
    48. Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristic of prostate cancer detected by digital rectal examination only. Urology. 2007; 70(6): 1117-20.
    49. Desireddi NW, Roehl KA, Loeb S, Yu X, Griffin CR, Kundu SK, Han M, Catalona WJ. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology. 2007;70(5): 950-955.
    50. Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW. External Validation of the UCSF-CAPRA Score. Urology. 2008; 72(2): 396-400.  
    51. Hernandez DJ, Nielsen ME, Han M, Partin AW: Contemporary evaluation of the D’Amico risk classification of prostate cancer. Urology. 2007; 70(5): 931-5.
    52. Hernandez DJ, Nielsen ME, Han M, Trock BJ, Partin AW, Walsh PC, Epstein JI. Natural History of Organ-Confined, Gleason < 6 Prostate Cancer Following Radical Prostatectomy. Urology 2008; 72(1): 172-6.
    53. Loeb S, Hernandez DJ, Mangold LA, Humphreys EB, Agro M, Partin AW, Han M. Progression Outcome after Radical Prostatectomy for Men in their 30’s compared to older men. BJU Int. 2008; 101(12): 1503-6.
    54. Magheli A, Rais-Bahrami S, Trock BJ, Humpheys EB, Partin AW, Han M, Gonzalgo ML. Prostate Specific Antigen versus Prostate Specific Antigen Density as a Prognosticator of Pathological Characteristics and Biochemical Recurrence Following Radical Prostatectomy. J Urol. 2008; 179(5): 1780-4.
    55. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, Gonzalgo ML. Impact of Body Mass Index on Biochemical Recurrence Rates After Radical Prostatectomy: An Analysis Utilizing Propensity Score Matching. Urology. 2008; 72(6): 1246-51.
    56. Wu I, Nielsen ME, Han M, Partin AW, Makarov DV. Does Laterality of Positive Needle Biopsy in Clinical T2a Patients with Prostate Cancer Affect Biochemical Recurrence-Free Survival? Urol. 2008;72(6):1219-23
    57. Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, Catalona WJ. Tumor characteristics of carriers and noncarriers of the decode 8q24 prostate cancer susceptibility alleles. J Urol 2008; 179(6): 2197-201.
    58. Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, Walsh PC. Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men with Biochemical Recurrence After Radical Prostatectomy. JAMA 2008; 299(23): 2760-2769.
    59. Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, Bartsch G, Partin AW. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2008; Epub ahead of print.
    60. Hu R, Dunn TA, Wei S, Asharwal S, Veltri R, Humphreys EA, Han M, Partin AW, De Marzo AM, Isaacs WB, Bova GS, Luo J. Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone Refractory Prostate Cancer. Cancer Research. 2009 Jan 1: 69(1): 16-22.
    61. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009 Nov;182(5):2232-41. Epub 2009 Sep 24.
    62. Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug;182(2):491-6; discussion 496-8. Epub 2009 Jun
    63. Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, Bartsch G, Partin AW. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2009 Mar;103(5):609-14. Epub 2008 Oct 24.
    64. Pierorazio PM, Epstein JI, Humpheys E, Han M, Walsh PC, Partin AW. The Significance of a Positive Bladder Neck Margin after Radical Prostatectomy: The AJCC Pathologic Stage T4 Designation is not warranted. J Urol 2010: 183(1):151-7.
    65. Pierorazio PM, Guzzo TJ, Han M, Bivalacqua TJ, Epstein JI, Schaeffer EM, Schoenberg M, Walsh PC, Partin AW. Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. Urology. 2010;76(3):715-21.
    66. Pierorazio PM, Humphreys, E, Walsh PC, Partin AW, Han M. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians. BJU Int 2010;106(6):791-5.
    67. Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M. Prediction of Mortality Following Radical Prostatectomy by Charlson Comorbidity Index. Urology 2010 Sep;76(3):553-7.
    68. Roberts WB, Tseng K, Walsh PC, Han M. A Critical Appraisal of the Management of Rectal Injury During Radical Prostatectomy. Urology 2010; 76(5):1088-91.
    69. Han M, Trock BJ, Partin AW, Humphreys EB, Bivalacqua TJ, Guzzo TJ, Walsh PC. The Impact of Preoperative Erectile Dysfunction on Survival after Radical Prostatectomy. BJU Int. 2010 Jun 29. [Epub ahead of print]
    70. Han M, Kim C, Mozer P, Schafer F, Badaan S, Vigaru B, Tseng K, Petrisor D, Trock BJ, Stoianovici D. Tandem-Robot Assisted Laparoscopic Radical Prostatectomy (T-RALP) to Improve the Neurovascular Bundle Visualization: A Feasibility Study. Urology 2011; 77(2):502-6.
    71. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of Statin Use with Pathologic Tumor Characteristics and Prostate Cancer Recurrence after surgery. J Urol 2011;185(4):1268-73.
    72. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC, Platz EA. Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prevention Research  2011;4(4):544-51.
    73. Joshu CE, Mondul AM, Meinhold C, Humphreys EB, Han M, Walsh PC, Platz EA. Cigarette smoking and prostate cancer recurrence after prostatectomy: Retrospective cohort study. J Natl Cancer Inst. 2011;103(10):835-8.
    74. Huang Y, Isharwal S, Haese S, Chun FKH, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW, Veltri RW. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. BJU I 2011;107(10):1562-9.
    75. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ. Predicting Fifteen-Year Prostate Cancer-Specific Mortality following Radical Prostatectomy. J Urol 2011; 185(3):869-75.
    76. Stoianovici D, Han M: Tandem Robot Assisted Laparoscopic Radical Prostatectomy. Clinl Sci. 2009; 28-29.
    77. Schäfer F, Petrisor D, Kim C, Badaan S, Han M, Stoianovici D: A New Robot for TRUS Probe Manipulation. Engineering and Urology Society, 2010; 16-17.
    78. Makarov DV, Loeb S, Magheli A, Zhao K, Humphreys E, Gonzalgo ML, Partin AW, Han M. Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. World J Urol. 2011 Feb;29(1):11-4. Epub 2010 Dec 14.
    79. Pierorazio P, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, Partin AW. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy. J Urol 2011;185(5):1691-7.
    80. Magheli A, Gonzalgo ML, Su L-M, Guzzo TJ, Netto, G, Humphreys EB, Han M, Partin AW, Pavlovich CP. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU Int 2011;107(12):1956-62.
    81. Lotan TL, Gurel B, Sutcliff S, Esopi D, Liu W, Xu J, Hicks J, Park BH, Humphreys E, Partin AW, Han M, Netto GH, Isaacs WB, De Marzo AM.PTEN protein loss by immunostaining: analytic validation and prognostic indication for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 17(50):6563-73.
    82. Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA, Netto GJ. Increased gene copy number of ERG on chromosome 21 but not TMPRESS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol. 2011;24(11):1511-20.
    83. Pierorazio PM, Ross AE, Han M, Epstein JI, Partin AW, Schaeffer EM. Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. BJU Int 2012:109(7):988-93.
    84. Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol, 2012;187(5):1620-5.
    85. Chalfin H, Dinizo M, Trock BJ, Feng Z, Partin AW, Walsh PC, Humphreys E, Han M. Implications of surgical margin status on prostate cancer-specific survival. BJU Int. 2012 Jul 12. Doi: 10.1111/j.1464-410X.2012.11371.x.
    86. Han M, Chang D, Kim C, Lee BJ, Zuo Y, Kim HJ, Petrisor D, Trock BJ, Partin AW, Rodriguez R, Carter HB, Allaf M, Kim J, Stoianovici. Geometric Evaluation of Systematic Transrectal Ultrasound-Guided Prostate Biopsy. J Urol. 2012 Dec;188(6):2404-9. doi: 10.1016/j.juro.2012.07.107. Epub 2012 Oct 22.PMID 23088974
    87. Stoianovici D, Kim C, Schafer F, Huang C-M, Petrisor D, Han M. Endocavity Ultrasound Probe Manipulators. IEEE/ASME Transactions on Mechatronics. 2011; 99: 1-8.
    88. Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M. Causes of Death After Radical Prostatectomy at a Large Tertiary Center. J Urol 2012; 188(3): 798-802.
    89. Dluzniewski PJ, Wang M-H, Zheng SL, De Marzo AM, Drake CG, Fedor HL, Partin AW, Han M, Fallin MD,  Xu J, Isaacs WB, Platz EA. Variation in IL10 and Other Genes Involved in the Immune Response, Production and Detoxification of Reactive Oxygen Species, and the Repair of Oxidative DNA Damage and Risk of Prostate Cancer Recurrence. Cancer Epidemiology, Biomarkers & Prevention. 2012 Sep 25.
    90. Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, Epstein JI, Walsh PC, Trock BJ, Partin AW. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2012 July 26. Doi: 10.1111/j.1464-410X.2012.11324.x.
    91. Reese AC, Pierorazio PM, Han M, Partin AW. Contemporary Evaluation of the National Comprehensive Cancer Network Prostate Cancer Risk Classification System. Urology. 2012 Sep 18. Pii:S0090-4295(12)00862-X. doi:10.1016/j.urology.2012.07.040.
    92. Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM. Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU Int. 2012 Oct;110(8): 1122-8.
    93. Kopp RP, Han M, Partin AW, Humphreys E, Freedland SJ, Parsons JK.; Obesity and prostate enlargement in men with localized prostate cancer. BJU Int. 2011 Dec;108(11):1750-5.
    94. Pierorazio PM, Lin BM, Mullins JK, Hyndman ME, Schaeffer EM, Han M, Partin AW, Pavlovich CP. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. Urol Oncol. 2011 Jun 9.
    95. Pierorazio PM, Mullins JK, Eifler JB, Voth K, Hyams ES, Han M, Pavlovich CP, Bivalacqua TJ, Partin AW, Allaf ME, Schaeffer EM. Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer. BJU Int. 2013 Jan 28. doi: 10.1111/j.1464-410X.2012.11757.x. [Epub ahead of print]
    96. Ellis C, Partin AW, Han M, Epstein JI. Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. J Urol 2013 May 29. PMID: 23727307
    97. Sundi D, Ross AE, Humphreys EB, Han M, Partin AW, Carter HB, Schaeffer EM. African American Men With Very Low-Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them? J Clin Oncol. 2013 Jun 17.
    98. Reese AC, Landis P, Han M, Epstein JI, Carter HB. Expanded Criteria to Identify Men Eligible for Active Surveillance of Low-Risk Prostate Cancer at Johns Hopkins: A Preliminary Analysis. J Urol. 2013 May 13. PMID: 23680308
    99. González-Roibón N, Han JS, Lee S, Feng Z, Arslankoz S, Smith N, Pierorazio PM, Humphreys E, Deweese TL, Partin AW, Bivalacqua TJ, Han M, Trock B, Netto GJ. Comparison of biochemical recurrence-free survival between periprostatic and pelvic lymph node metastases of prostate cancer. Int J Surg Pathol. 2013 Aug;21(4):352-7. PMID: 23564700
    100. Ha YS, Salmasi A, Karellas M, Singer EA, Kim JH, Han M, Partin AW, Kim WJ, Lee DH, Kim IY. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance. Urology. 2013 Apr;81(4):831-5. PMID: 23465143  
    101. Kim C, Chang D, Petrisor D, Chirikjian G, Han M, Stoianovici D. Ultrasound probe and needle-guide calibration for robotic ultrasound scanning and needle targeting. IEEE Trans Biomed Eng. 2013 Jun;60(6):1728-34. PMID: 23358940
    102. Pierorazio PM, Mullins JK, Ross AE, Hyams ES, Partin AW, Han M, Walsh PC, Schaeffer EM, Pavolovich CP, Allaf ME, Bivalacqua TJ. Trends in immediate perioperative morbidity and delay in discharge after open and minimally invasive radical prostatectomy (RP): a 20-year institutional experience. BJU Int. 2013 Jul;112(1):45-53.
    103. Chalfin HJ, Frank SM, Feng Z, Trock BJ, Drake CG, Partin AW, Humphreys E, Ness PM, Jeong BC, Lee SB, Han M. Allogeneic versus autologous blood transfusion and survival after radical prostatectomy. Transfusion. 2014 Mar 6. Doi: 10.1111/trf.12611. [Epub ahead of print].
    104. Tseng KS, Kulkarni S, Hymphreys EB, Carter HB, Mostwin JL, Partin AW, Han M, Wu CL. Spinal anesthesia does not impact prostate cancer recurrence in a cohort of men undergoing radical prostatectomy: An observational study. Regional Anesthesia and Pain Medicine. 2014. 39 (4): 284-288. Doi: 10.1097/AAP.0000000000000108.
    105. Sundi D, Wang V, Pierorazio PM, Han M, Partin AW, Tran PT, Ross AE, Bivalacqua TJ. Identification of men with the highest risk of early disease recurrence after radical prostatectomy. Prostate. 2014 Jan 22. doi: 10.1002/pros.22780. [Epub ahead of print] PMID: 24453066.
    106. Sundi D, Wang VM, Pierorazio PM, Han M, Bivalacqua TJ, Ball MW, Antonarakis ES, Partin AW, Schaeffer EM, Ross AE. Very-high-risk localized prostate cancer: definition and outcomes. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63. doi: 10.1038/pcan.2013.46. Epub 2013 Nov 5. PMID: 24189998.
    107. Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, Han M, Epstein JI, Partin AW, Walsh PC, Bivalacqua TJ. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate. 2013 Nov;73(15):1673-80. doi: 10.1002/pros.22702. Epub 2013 Sep 9. PMID: 24019101.
    108. Faisal FA, Sundi D, Pierorazio PM, Ball MW, Humphreys EA, Han M, Epstein JI, Partin AW, Carter HB, Bivalacqua TJ, Schaeffer EM, Ross AE. Outcomes of men with an elevated PSA as their sole preoperative intermediate or high risk feature. BJUI. 2014 Apr 15. Doi: 10.1111/bju.12771.
    109. Faisal FA, Sundi D, Cooper JL, Humphreys EB, Partin AW, Han M, Ross AE, Schaeffer EM. Racial disparities in oncologic outcomes after radical prostatectomy: Long-term follow-up. Urology. 1 December 2014 84(6):1434-1441. Doi: 10/1016/j.urology.2014.08.039. PID: 25432835.
    110. Chalfin HJ, Lee SB, Jeong BC, Freedland SJ, Feng Z, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M. Obesity and Long-Term Survival after Radical Prostatectomy. J Urol. 2014. Apr 21. Doi: 10.1016/j.juro.2014.04.086.
    111. Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M. The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. Eur Urol. Feb 2015. 67 (2): 342-346. 
    112. Park S-W, Readal N, Jeong BC, Humphreys EB, Epstein JI, Partin AW, Han M. Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. Eur Urol. 2015 Aug;68(2):311-6. doi: 10.1016/j.eururo.2014.07.012. Epub 2014 Jul 31. PMID:25088822.
    113. Lotan TL, Carvalho FLF, Peskoe SB, Hicks JL, Good J, Fedor HL, Humphreys E, Han M, Platz EA, Squire JA, De Marzo AM, Berman DM. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathol. 2015(28)128-137. Doi: 10.1028/modpathol.2014.85. Epub 4 July 2014.
    114. Patel HD, Humphreys E, Trock BJ, Han M, Carter HB. Practice patterns and individual variability of surgeons performing radical prostatectomy at a high volume academic center. J Urol. 2015. 193 (3): 812-819. Doi: 10.1016/j.juro.2014.08.101.
    115. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer 2015. Doi: 10.1002/cncr.29147.
    116. Ko KS, Chalfin H, Trock BJ, Feng Z, Humphreys E, Park S-W, Carter HB, Frick KD, Han M. Variability in Medicare Utilization and Payment among Urologists. Urology 2015 May;85(5):1045-50. doi: 10.1016/j.urology.2014.11.054. Epub 2015 Mar 4. PMID: 25746578.
    117. Ko JS, Chalfin H, Han M. Reply: To PMID 25746578. Urology. 2015 May;85(5):1051. doi: 10.1016 /j.urology.2014.11.056. Epub 2015 Mar 4. PMID: 25746577.
    118. Prueitt R, Wallace TA, Glynn SA, Yi M, Tang W, Luo J, Dorsey TH, Stagliano KE, Gillespie JW, Hudson RS, Terunuma A, Shoe JL, Haines DC, Yfantis HG, Han M, Martin DN, Jordan SV, Borin JF, Naslund MJ, Alexander RB, Stephens RM, Loffredo CA, Lee DH, Putluri N, Sreekumar A, Hurwitz AA, Ambs S. An immune-inflammation gene expression signature in prostate tumors of smokers. Cancer Res. 2015 Dec 30. pii: canres.3630.2014. [Epub ahead of print] PMID: 26719530.
    119. Gann PH, Deaton RJ, Rueter EE, van Breemen RB, Nonn L, Macias V, Han M, Ananthanarayanan V. A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. Nutr Cancer. 2015;67(7):1104-12. Doi: 10/1080/01635581.2015.1075560. PMID: 26422197.
    120. Ludwig WW, Gorin MA, Ball MW, Schaeffer EM, Han M, Allaf ME. Instrument Life for Robot-assisted Laparoscopic Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified? Urology. 2015 Nov86(5):94206. doi: 10.1016/j.urology.2015.05.047. Epub 2015 Aug 12. PMID: 26276575.
    121. Kates M, Sopko NA, Han M, Partin AW, Epstein JI. Importance of Reporting the Gleason Score at the positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. J Urol. 2015 Aug 8. pii: S0022-5347(15)04530-9. doi: 10.1016/j.juro.2015.08.002. [Epub ahead of print] PMID: 26264998.
    122. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2015 Jul 9. pii: S0302-2838(15)00557-6. doi: 10.1016/j.eururo.2015.06.046. [Epub ahead of print] PMID: 26166626.
    123. Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med. 2015 Jul;56(7):1003-10. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11. PMID: 26069305.
    124. Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol. 2016 Jan;69(1):157-65. doi: 10.1016/j.eururo.2015.05.042. Epub 2015 Jun 6. PMID: 26058959.
    125. Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. Eur Urol. 2015 Apr 25. pii: S0302-2838(15)00318-8. doi: 10.1016/j.eururo.2015.04.016. [Epub ahead of print] PMID: 25922274.

Book Chapters, Monographs:   

  1. Han M, Polascik TJ: Chap 5. Urologic procedures.  Johns Hopkins Manual of Common Bedside Surgical Procedures.  Chen H, Sonnandy C, Lillemoe K (eds).  Williams Wilkins. 206-236, 1999. 
  2. Han M, Schoenberg MP: In vitro testing of bladder tumor.  American Urological Association Update Series   Vol XX, Lesson 28, 218-23, 2001.
  3. Han M, Partin AW: Chap IV.  Anatomic radical retropubic prostatectomy for prostate cancer.  Prostate cancer in the 21st century. Chung L, Isaacs J, Simons J (eds). Humana Press Inc. 377-386, 2001.
  4. Han M, Alfert H, Partin AW: Chap 41, Retropubic and suprapubic open prostatectomy.  Campbell’s Urology, 8th Ed, Walsh, Retik, Vaughan, Wein (eds).  Saunders    Vol 2.1423-34, 2002.
  5. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: The 15-year Johns Hopkins experience.  Urologic Clinics of North America 2001 Aug; 29 (3):555-65, 2001.
  6. Han M, Catalona WJ: Anatomic Nerve-Sparing Radical Retropubic Prostatectomy.  Urologic Oncology   Chap 29: 514-27, 2004.
  7. Han M, Catalona WJ: What Is the Best PSA Prompt for Biopsy? AUA News March;9(2):30-1, 2004.
  8. Han M, Catalona WJ: New Markers for Prostate Cancer. Urologia Contemporânea 2005.
  9. Han M, Catalona WJ: New Markers for Prostate Cancer: Renal and Urology News July/August. 39-40, 2004.
  10. Han M, Partin AW: Multivariate Models for Predicting Pathological Stage. Prostate Cancer: Principles and Practice, Kirby, Fenley, Parsons, Partin (eds). 565-567, 2006.
  11. Han M, Catalona WJ: New Concepts in Early Detection of Prostate Cancer. Prostate Cancer: Principles and Practice, Kirby, Fenley, Parsons, Partin. 415-425, 2006.
  12. Han M, Partin AW: Chapter 89, Retropubic and suprapubic open prostatectomy. Campbell-Walsh Urology, 9th edition, Wein, Kavoussi, Novick, Partin, and Peters. Saunders. 2007.
  13. Han M, Catalona WJ:  Chapter 95, Definitive Therapy for Localized Prostate Cancer. Campbell-Walsh Urology, 9th edition, Wein, Kavoussi, Novick, Partin, and Peters. Saunders. 2007.
  14. Loeb S, Han M, Catalona WJ: Prostate-Specific Antigen and Prostate Cancer Screening. Prostate Biopsy, Jones. Humana Press, 2008.
  15. Han M, Partin AW: Chap 94. Retropubic and suprapubic open prostatectomy. Campbell-Walsh Urology, 10th Ed, Wein, Kavoussi, Novick, Partin, Peters (eds). Saunders: 2695-2703, 2010.
  16. Catalona WJ, Han M:  Chap 100, Definitive Therapy for Localized Prostate Cancer. Campbell-Walsh Urology, 10th Ed, Wein, Kavoussi, Novick, Partin, Peters (eds). Saunders: 2771-2788, 2010.
  17. Roberts WB, Han M: Chap 19, Genitourinary Medicine. Oxford American Handbook of Geriatric Medicine, Durso (ed). Oxford. 529-551. 2010.
  18. Sundi D, Han M: Adrenal insufficiency, acute (adrenal crisis). 5 Minute Urology Consult. 3rd Ed, Gomella. 2014.
  19. Sundi D, Han M: Prostate cancer, metastatic. 5 Minute Urology Consult. 3rd Ed, Gomella. 2014.
  20. Sundi D, Han M: Rectal injury during radical prostatectomy or radical cystectomy. 5 Minute Urology Consult. 3rd Ed, Gomella. 2014.


  1. Parsons JK, Eifler JB, Han M (eds). Johns Hopkins Handbook of Urology, Wiley, Oxford. 2013.


  1. Han M, Chan DY, Jackman SV, Fabrizio MF, Kavoussi LR, Jarrett TW: The "Mini-Perc" technique: a less invasive alternative to standard percutaneous nephrolithotomy. Presented at 94th AUA Annual Meeting, V47, Dallas, TX, May  AUA Video Library HV 2209, 1999.
  2. Han M, Kim C, Mozer P, Badaan S, Vigaru B, Schafer F, Tseng K, Petrisor D, Trock B, Stoianovici D: Tandem Robot Assisted Laparoscopic Radical Prostatectomy: Clinical Feasibility study for Neurovascular Bundle Visualization. Video presented at World Congress of Endourology meeting, 2009.
  3. Chalfin H, Kim C, Trock B, Petrisor D, Lee D, Kim H, Stoianovici D, Han M: Tandem-Robot Assisted Laparoscopic Prostatectomy. Video presented at annual American Urological Association meeting, Washington, DC. 2011
  4. Park SW, Jayram T, Szima-Cotter P, Han M: Robotic-assisted Laparoscopic Simple Prostatectomy: Technique and Outcomes. Abstract 14-1138. Video presented at annual American Urological Association meeting, Orlando, FL. 2014


  • American Urological Association
  • American Urological Association, North Central Section
  • American Medical Association

Awards & Honors

1988-1992 Dean's List, School of Arts and Sciences, Johns Hopkins University
  Phi Beta Kappa
  Graduated with General and Departmental Honors
AUA 2000 (ACMI-Circon) resident’s essay contest, clinical research, third prize
AUA 2001 (Astro-Zeneca) resident’s essay contest, clinical research, first prize
"Ability of an artificial neural network predicts progression free survival for men with Gleason score 3+4 versus Gleason score 4+3 tumors following radical prostatectomy."
AUA 2002 (Astro-Zeneca) resident’s essay contest, clinical research, second prize
"Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer"
Mid-Atlantic Section AUA 2000 Resident's essay contest, clinical research, second prize
"Prediction of biochemical (PSA) recurrence following radical prostatectomy for clinically
localized prostate cancer."
5/2002 Praecis scholar in urology, AUA, Chicago, IL
4/2002 Pfizer scholar in urology, Johns Hopkins Hospital
5/2003 Prostate Cancer SPORE career development award,Northwestern Memorial Hospital
10/2003 Northwestern University Clinical Investigator Training Program Scholar (recipient of tuition support through NIH Clinical Research Curriculum Award (K30))
2004 Visiting Professor, Korea Prostate Society, Pusan, Korea
2007 Faculty Teaching Award, Department of Urology, Johns Hopkins Hospital

Moderator, Engineering and Urology Society, AUA Annual meeting

2009 Best Paper Award, Engineering and Urology Society, AUA Annual meeting
2009 Moderator, Engineering and Urology Society, AUA Annual meeting
2009 Best Clinical Presentation Award, Sexual Medicine Society of North America, SMSNA Annual meeting, San Diego, CA
2010 Moderator, Engineering and Urology Society, AUA Annual meeting

Moderator, Resident Essay Contest, Mid-Atlantic AUA meeting

2013 Alpha Omega Alpha Honor Medical Society